Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenDynamic bone quality: a noninvasive measure of bone's biomechanical property in osteoporosisMagnetic resonance imaging assessed cortical porosity is highly correlated with μCT porosity.Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Off-axis loads cause failure of the distal radius at lower magnitudes than axial loads: a finite element analysis.Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.Osteopenia: a diagnostic and therapeutic challengeEffectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort studyFracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practiceParametric response mapping of CT images provides early detection of local bone loss in a rat model of osteoporosis.Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based AnalysisRelationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.Treating osteoporosis: economic aspects of bisphosphonate therapy.High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group.European guidance for the diagnosis and management of osteoporosis in postmenopausal women.DXA scanning in clinical practice.Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Treatment responses with once-weekly teriparatide therapy for osteoporosis.Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.Measuring bone quality.Co-administration of antiresorptive and anabolic agents: a missed opportunity.Goal-directed treatment of osteoporosis.Factors Affecting Bone Mineral Density Measurement after Fracture in South Korea.Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography.Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.Evolve osteoporosis and other guidelines avoiding cognitive bias.Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver TransplantationTreatment failure in osteoporosisGoal-directed therapy in osteoporosis
P2860
Q24612411-C1E461C7-014D-40CB-AC2D-EAB8DD75649BQ30476071-4C79BCE6-E8A0-4054-9621-68C19F5A24BFQ30831057-2643D394-D910-4A40-99C9-05F3A153734EQ33931909-18AE4897-6AEA-4759-BBD9-E9BE6924FB8FQ33956586-D2592B74-6E27-4C75-ACC0-1EC1582973DAQ34009569-F851D3C0-792F-461A-8C5F-3CBF533EA80FQ34626494-C94ED8A7-FD7E-4134-83F8-1924589CEA61Q35017714-BFB0BB9F-485F-4071-8EB6-E4A9D33EB1A9Q35144237-12BDC0FB-2258-48E9-8356-261787259051Q35230210-8213FFF7-229D-4653-9857-D483F90DE65BQ35536507-F613A1A2-A4AF-4EE8-8B76-629E368AE9A3Q35653722-AE578769-095C-49EC-AD89-19AFF3FE7732Q35678676-D45AEC1F-B11D-498F-B573-9B8F0994BCB6Q35774970-905511B7-8E7C-4AD5-B551-3DB97D8402A6Q35961807-FCB0054D-6849-4C27-B465-E14E861975DDQ36019924-386FB838-6AEA-40DE-8A83-9A8926F1A0D0Q36045845-8B5CBB4D-755D-421A-8E50-F7E123EEDD12Q36153174-50B14410-F6E5-4343-90EE-45A098B4A217Q36543142-642ECE0F-4723-4440-A965-E53D7F8CA7BCQ36809342-178492C2-C96C-400E-9113-E0AAAD451DCFQ37037296-29C06F3C-EF8A-4AC4-8308-1588F19CE980Q37107665-0F42E705-0F61-4955-B501-6CA7B730CD34Q37135281-8E84C9AD-5BA6-477A-906A-BA7C863FF895Q37298025-7581F54D-FC69-46DD-B1EC-81ECE0EC53F2Q37731292-D153204F-6710-4775-92B4-4420C1FD6EC5Q38029394-FE655C34-D648-47FD-8019-05DFD4AC4801Q38145005-7C761C29-97E7-4334-AAF8-B134220C341EQ38367370-911BDC70-CB0A-4ECB-B82D-67A5F6C31FE4Q44874767-54014912-CFCF-4890-84C3-DD3457085EFEQ47189134-B320EB63-3340-42AA-9EA1-2E53449DC1A5Q51369601-5B3049CF-5DBF-4834-9E36-9332D052DD4FQ51482952-6C03C41A-DA3A-40D0-AC78-7E2C83C1EC84Q53221347-3BD79EBC-0B75-4012-B41B-43774D1565ACQ57168211-D6FCA2D7-8FBA-460F-90E0-1D85ABB814F3Q57417008-A6AA4090-546F-4AD3-A85B-B20A8953A1E6Q57711404-BA1AFAC3-35A9-4B6D-97E8-EF0D95DBEC74
P2860
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Relationship between changes i ...... not related to change in BMD.
@en
Relationship between changes i ...... not related to change in BMD.
@nl
type
label
Relationship between changes i ...... not related to change in BMD.
@en
Relationship between changes i ...... not related to change in BMD.
@nl
prefLabel
Relationship between changes i ...... not related to change in BMD.
@en
Relationship between changes i ...... not related to change in BMD.
@nl
P2093
P356
P1476
Relationship between changes i ...... not related to change in BMD.
@en
P2093
Dieter Felsenberg
Ian P Barton
Nelson B Watts
Piet Geusens
P304
P356
10.1359/JBMR.050814
P577
2005-08-08T00:00:00Z